Purvish M. Parikh

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

Iressa Survival Evaluation, Medicine, Cancer Management +6

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2006 · 702 citations · Full text

Challenges to effective cancer control in China, India, and Russia

Paul E. Goss, Kathrin Strasser‐Weippl, Brittany Bychkovsky et al. · The Lancet Oncology · 2014 · 497 citations

Medicine, Global Health, Cancer Management +9

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Alex Y. Chang, Purvish M. Parikh, Sumitra Thongprasert et al. · Journal of Thoracic Oncology · 2006 · 168 citations · Full text

Isel Study, Oncology, Asian Origin +7

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Alex Y. Chang, Purvish M. Parikh, Sumitra Thongprasert et al. · Journal of Thoracic Oncology · 2006 · 129 citations

Isel Study, Oncology, Asian Origin +7